Gustave Roussy, Cancer Campus, Grand Paris

This study tests a new drug called DS-1062a in 100 people with advanced lung cancer that has not responded to other treatments. The drug is given every three weeks and aims to shrink tumors. Researchers will also study how the drug affects the immune system and look for markers t…

This study looks at people with low-risk papillary thyroid cancer (tumors 11-40 mm). It compares two surgeries: removing the thyroid alone versus removing the thyroid plus nearby lymph nodes in the neck. The goal is to see if the extra lymph node removal leads to better remission…

This study tests whether giving immunotherapy (anti-PD1) before and after surgery, along with standard treatments, can help people with a rare type of melanoma in the head and neck area live longer without the cancer coming back. About 60 adults with resectable tumors will receiv…

This study aimed to test a combination of two drugs (atezolizumab and tiragolumab) in people with advanced lung cancer that has special immune cell clusters called tertiary lymphoid structures. It planned to include patients who had not received prior treatment or who had already…

This study tests the immunotherapy drug nivolumab in children and adults with a rare type of lymphoma (ALK+ anaplastic large cell lymphoma) that has come back or not responded to standard treatment. The trial has two groups: one for people with active disease to see if the drug s…

This study tests whether a precise, high-dose radiation treatment called stereotactic body radiation therapy (SBRT) can help control breast cancer that has spread to a few spots in the body. About 154 women with metastatic breast cancer who are starting their first treatment will…

This early-phase trial tests whether adding the targeted drug regorafenib to standard chemotherapy is safe for people with newly diagnosed, widespread Ewing sarcoma. The study enrolls about 23 patients aged 2 to 49 whose cancer has spread beyond the lungs. The goal is to find a s…

This study looks at whether a more intensive follow-up schedule after treatment for head and neck cancer helps people live longer compared to the usual schedule. It includes 197 smokers or heavy drinkers over age 35 who are cancer-free 2-4 months after treatment. Participants are…

This study was designed for adults with certain types of soft tissue sarcoma that have specific immune cell clusters (TLS). It aimed to test if adding a DNA repair inhibitor (olaparib) to immunotherapy (pembrolizumab) before surgery could boost the immune response. However, the s…

This study explores whether growing a patient's tumor cells into tiny 3D organoids in the lab can help doctors choose the most effective treatment. It includes 152 adults with advanced solid cancers that have stopped responding to standard therapies. Researchers will test differe…